Renoproctective effect of hight periprocedural doses of oral N- ACETYLCYSTEINE in patients scheduled to undergo a same - day angiography

BACKGROUND: Few studies that have assessed the effect of abbrcviated oral Nacctylcysteine (NAC) rcgimens in radiocontrast-induced nephropat hy (RCIN)yield mixed results. OBJECTJVE: To evaluate the rcnoprotective effect of high periprocedural oral doses (HPOD) of NAC in patients with chronic renal im...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Baderramo, Domingo, Badra Verdu, Mariano, Ramacciotti , Constanza, Cremona, Luis, Lemos, Pablo, Orías, Marcelo, Moreyra Jr, Eduardo
Formato: Artículo revista
Lenguaje:Español
Publicado: Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología 2004
Materias:
N-acetylcysteine
contrast media
angiography
acute renal failure
N- acetilcisteina
Medio de contraste
Angiografía
Insuficiencia renal aguda
Acceso en línea:https://revistas.unc.edu.ar/index.php/med/article/view/33031
Aporte de:
Revista de la Facultad de Ciencias Médicas de Córdoba de Universidad Nacional de Córdoba
Descripción
Sumario:BACKGROUND: Few studies that have assessed the effect of abbrcviated oral Nacctylcysteine (NAC) rcgimens in radiocontrast-induced nephropat hy (RCIN)yield mixed results. OBJECTJVE: To evaluate the rcnoprotective effect of high periprocedural oral doses (HPOD) of NAC in patients with chronic renal impairmcnt undergoing a same-day angiography. METHODS: Sixty one paticnts vi1Ii renal impaired function scheduled to undcrgo a same-day angiography were randomly assigned to NAC 1200 ing orally 3 hours before and 3 after the procedure, or a placebo. Al! patients received 0.9% salme intravenous. RCIN was defined as an increase in SCC > 0.5 mg/dl 48 hours after the procedure. RESULTS: The mean baseline SCC for all patients was 1.44 ± 0.42 mg/dl. A slgnificant difference in SCC change at 48 hours after the angiography was found (-0.07 mg/dl NAC, 0.09 mg/dl placebo, P=0.04). RCIN occurred in 1 (3%)patient of NAC group and in 2 (7.1%) patients of placebo group (P=0.59). Adverse effects were similar in both groups. CONCLUSIONS: In patients withmild renal impairment patients undergoing angiographic procedures. HPOD of NAC were more effective than placebo in preventing SCC change 48 hours. A non slgnlficant benefit in RCIN incidence vas found.

Ejemplares similares